Improvement Effect of Bifidobacterium animalis subsp. lactis MH-02 in Patients Receiving Resection of Colorectal Polyps: A Randomized, Double-Blind, Placebo-Controlled Trial
BackgroundPostoperative symptoms, bowel dysfunction and recurrence are common problems after resection of colorectal polyps. We aimed to evaluate the efficacy of Bifidobacterium in the postoperative patients.MethodsIn this single-center, randomized, double-blind, placebo-controlled trial, adults (≥...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-06-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.940500/full |
| _version_ | 1811333945970655232 |
|---|---|
| author | Hui Liu Hui Liu Kaige Zhang Kaige Zhang Peng Liu Xuan Xu Yuyang Zhou Yuyang Zhou Lihong Gan Ling Yao Bin Li Tingtao Chen Nian Fang Nian Fang |
| author_facet | Hui Liu Hui Liu Kaige Zhang Kaige Zhang Peng Liu Xuan Xu Yuyang Zhou Yuyang Zhou Lihong Gan Ling Yao Bin Li Tingtao Chen Nian Fang Nian Fang |
| author_sort | Hui Liu |
| collection | DOAJ |
| description | BackgroundPostoperative symptoms, bowel dysfunction and recurrence are common problems after resection of colorectal polyps. We aimed to evaluate the efficacy of Bifidobacterium in the postoperative patients.MethodsIn this single-center, randomized, double-blind, placebo-controlled trial, adults (≥ 18 years) undergoing endoscopic resection of colorectal polyps were treated with probiotics (Bifidobacterium animalis subsp. lactis MH-02, 2 × 109 colony-forming units per packet) or placebo once daily for 7 days. The primary clinical endpoint was a reduction in the mean total postoperative symptoms score within 7 days postoperatively. Secondary clinical endpoints were the single symptom scores, time to recovery of bowel function, and changes in the intestinal microbiota. This study is registered with the number ChiCTR2100046687.ResultsA total of 100 individuals were included (48 in probiotic group and 52 in placebo group). No difference was seen in the mean scores between the two groups (0.29 vs. 0.43, P = 0.246). Colorectal polyps size (P = 0.008) and preoperative symptoms (P = 0.032) were influential factors for the primary endpoint. Besides, MH-02 alleviated difficult defecation (P = 0.045), and reduced the time to recovery of bowel function (P = 0.032). High-throughput analysis showed that MH-02 can help restore the diversity of intestinal microbiota, and increased the relative abundance of Bifidobacterium, Roseburia, Gemmiger, Blautia and Ruminococcus, while reduced the relative abundance of Clostridium at genus level (P < 0.05).ConclusionIn this prospective trial, MH-02 showed efficacy in patients with resection of colorectal polyps, particularly in the recovery of bowel function, and the changes in the intestinal microbiota may provide evidence for further exploration of the therapeutic mechanisms. |
| first_indexed | 2024-04-13T17:00:24Z |
| format | Article |
| id | doaj.art-5bb88f54cefd41da963ec23ba38424ba |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-13T17:00:24Z |
| publishDate | 2022-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-5bb88f54cefd41da963ec23ba38424ba2022-12-22T02:38:41ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-06-011310.3389/fimmu.2022.940500940500Improvement Effect of Bifidobacterium animalis subsp. lactis MH-02 in Patients Receiving Resection of Colorectal Polyps: A Randomized, Double-Blind, Placebo-Controlled TrialHui Liu0Hui Liu1Kaige Zhang2Kaige Zhang3Peng Liu4Xuan Xu5Yuyang Zhou6Yuyang Zhou7Lihong Gan8Ling Yao9Bin Li10Tingtao Chen11Nian Fang12Nian Fang13Third Clinical Medical College, Nanchang University, Nanchang, ChinaDepartment of Gastroenterology, The First Hospital of Nanchang (The Third Affiliated Hospital of Nanchang University), Nanchang, ChinaThird Clinical Medical College, Nanchang University, Nanchang, ChinaDepartment of Gastroenterology, The First Hospital of Nanchang (The Third Affiliated Hospital of Nanchang University), Nanchang, ChinaDepartment of Gastroenterology, The First Hospital of Nanchang (The Third Affiliated Hospital of Nanchang University), Nanchang, ChinaHuankui Academy, Nanchang University, Nanchang, ChinaThird Clinical Medical College, Nanchang University, Nanchang, ChinaDepartment of Gastroenterology, The First Hospital of Nanchang (The Third Affiliated Hospital of Nanchang University), Nanchang, ChinaDepartment of Gastroenterology, The First Hospital of Nanchang (The Third Affiliated Hospital of Nanchang University), Nanchang, ChinaDepartment of Gastroenterology, The First Hospital of Nanchang (The Third Affiliated Hospital of Nanchang University), Nanchang, ChinaDepartment of Gastroenterology, The First Hospital of Nanchang (The Third Affiliated Hospital of Nanchang University), Nanchang, ChinaNational Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Nanchang University, Nanchang, ChinaThird Clinical Medical College, Nanchang University, Nanchang, ChinaDepartment of Gastroenterology, The First Hospital of Nanchang (The Third Affiliated Hospital of Nanchang University), Nanchang, ChinaBackgroundPostoperative symptoms, bowel dysfunction and recurrence are common problems after resection of colorectal polyps. We aimed to evaluate the efficacy of Bifidobacterium in the postoperative patients.MethodsIn this single-center, randomized, double-blind, placebo-controlled trial, adults (≥ 18 years) undergoing endoscopic resection of colorectal polyps were treated with probiotics (Bifidobacterium animalis subsp. lactis MH-02, 2 × 109 colony-forming units per packet) or placebo once daily for 7 days. The primary clinical endpoint was a reduction in the mean total postoperative symptoms score within 7 days postoperatively. Secondary clinical endpoints were the single symptom scores, time to recovery of bowel function, and changes in the intestinal microbiota. This study is registered with the number ChiCTR2100046687.ResultsA total of 100 individuals were included (48 in probiotic group and 52 in placebo group). No difference was seen in the mean scores between the two groups (0.29 vs. 0.43, P = 0.246). Colorectal polyps size (P = 0.008) and preoperative symptoms (P = 0.032) were influential factors for the primary endpoint. Besides, MH-02 alleviated difficult defecation (P = 0.045), and reduced the time to recovery of bowel function (P = 0.032). High-throughput analysis showed that MH-02 can help restore the diversity of intestinal microbiota, and increased the relative abundance of Bifidobacterium, Roseburia, Gemmiger, Blautia and Ruminococcus, while reduced the relative abundance of Clostridium at genus level (P < 0.05).ConclusionIn this prospective trial, MH-02 showed efficacy in patients with resection of colorectal polyps, particularly in the recovery of bowel function, and the changes in the intestinal microbiota may provide evidence for further exploration of the therapeutic mechanisms.https://www.frontiersin.org/articles/10.3389/fimmu.2022.940500/fullBifidobacteriumMH-02colorectal polypspostoperative symptomsintestinal microbiota |
| spellingShingle | Hui Liu Hui Liu Kaige Zhang Kaige Zhang Peng Liu Xuan Xu Yuyang Zhou Yuyang Zhou Lihong Gan Ling Yao Bin Li Tingtao Chen Nian Fang Nian Fang Improvement Effect of Bifidobacterium animalis subsp. lactis MH-02 in Patients Receiving Resection of Colorectal Polyps: A Randomized, Double-Blind, Placebo-Controlled Trial Frontiers in Immunology Bifidobacterium MH-02 colorectal polyps postoperative symptoms intestinal microbiota |
| title | Improvement Effect of Bifidobacterium animalis subsp. lactis MH-02 in Patients Receiving Resection of Colorectal Polyps: A Randomized, Double-Blind, Placebo-Controlled Trial |
| title_full | Improvement Effect of Bifidobacterium animalis subsp. lactis MH-02 in Patients Receiving Resection of Colorectal Polyps: A Randomized, Double-Blind, Placebo-Controlled Trial |
| title_fullStr | Improvement Effect of Bifidobacterium animalis subsp. lactis MH-02 in Patients Receiving Resection of Colorectal Polyps: A Randomized, Double-Blind, Placebo-Controlled Trial |
| title_full_unstemmed | Improvement Effect of Bifidobacterium animalis subsp. lactis MH-02 in Patients Receiving Resection of Colorectal Polyps: A Randomized, Double-Blind, Placebo-Controlled Trial |
| title_short | Improvement Effect of Bifidobacterium animalis subsp. lactis MH-02 in Patients Receiving Resection of Colorectal Polyps: A Randomized, Double-Blind, Placebo-Controlled Trial |
| title_sort | improvement effect of bifidobacterium animalis subsp lactis mh 02 in patients receiving resection of colorectal polyps a randomized double blind placebo controlled trial |
| topic | Bifidobacterium MH-02 colorectal polyps postoperative symptoms intestinal microbiota |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.940500/full |
| work_keys_str_mv | AT huiliu improvementeffectofbifidobacteriumanimalissubsplactismh02inpatientsreceivingresectionofcolorectalpolypsarandomizeddoubleblindplacebocontrolledtrial AT huiliu improvementeffectofbifidobacteriumanimalissubsplactismh02inpatientsreceivingresectionofcolorectalpolypsarandomizeddoubleblindplacebocontrolledtrial AT kaigezhang improvementeffectofbifidobacteriumanimalissubsplactismh02inpatientsreceivingresectionofcolorectalpolypsarandomizeddoubleblindplacebocontrolledtrial AT kaigezhang improvementeffectofbifidobacteriumanimalissubsplactismh02inpatientsreceivingresectionofcolorectalpolypsarandomizeddoubleblindplacebocontrolledtrial AT pengliu improvementeffectofbifidobacteriumanimalissubsplactismh02inpatientsreceivingresectionofcolorectalpolypsarandomizeddoubleblindplacebocontrolledtrial AT xuanxu improvementeffectofbifidobacteriumanimalissubsplactismh02inpatientsreceivingresectionofcolorectalpolypsarandomizeddoubleblindplacebocontrolledtrial AT yuyangzhou improvementeffectofbifidobacteriumanimalissubsplactismh02inpatientsreceivingresectionofcolorectalpolypsarandomizeddoubleblindplacebocontrolledtrial AT yuyangzhou improvementeffectofbifidobacteriumanimalissubsplactismh02inpatientsreceivingresectionofcolorectalpolypsarandomizeddoubleblindplacebocontrolledtrial AT lihonggan improvementeffectofbifidobacteriumanimalissubsplactismh02inpatientsreceivingresectionofcolorectalpolypsarandomizeddoubleblindplacebocontrolledtrial AT lingyao improvementeffectofbifidobacteriumanimalissubsplactismh02inpatientsreceivingresectionofcolorectalpolypsarandomizeddoubleblindplacebocontrolledtrial AT binli improvementeffectofbifidobacteriumanimalissubsplactismh02inpatientsreceivingresectionofcolorectalpolypsarandomizeddoubleblindplacebocontrolledtrial AT tingtaochen improvementeffectofbifidobacteriumanimalissubsplactismh02inpatientsreceivingresectionofcolorectalpolypsarandomizeddoubleblindplacebocontrolledtrial AT nianfang improvementeffectofbifidobacteriumanimalissubsplactismh02inpatientsreceivingresectionofcolorectalpolypsarandomizeddoubleblindplacebocontrolledtrial AT nianfang improvementeffectofbifidobacteriumanimalissubsplactismh02inpatientsreceivingresectionofcolorectalpolypsarandomizeddoubleblindplacebocontrolledtrial |